Norris medicines Limited has announced the approval of its unaudited financial results for the quarter and year ended December 31, 2025. The pharmaceutical company's Board of Directors held a meeting on February 14, 2026, to review and approve these quarterly financial results in compliance with regulatory requirements.

Board Meeting Details

The board meeting was conducted pursuant to Regulation 30 and 33 of the SEBI (Listing Obligations & Disclosure Requirements) Regulations, 2015. The meeting provided a comprehensive review of the company's financial performance for the specified period.

Financial Results Approval

The Board of Directors considered and approved the unaudited financial results along with the Limited Review Report for the quarter and year ended December 31, 2025. This approval was made in continuation of the company's earlier communication dated February 11, 2026, which had intimated the scheduled date of the board meeting.

The financial results were prepared in accordance with Chapter IV read with Schedule III of the SEBI (Listing Obligations & Disclosure Requirements) Regulations, 2015. The company has attached these results as Annexure I to their regulatory filing.

Regulatory Compliance

Norris Medicines Limited has committed to publishing the approved financial results in newspapers following the format prescribed under Regulation 47 of the Listing Regulations. This step ensures transparency and compliance with disclosure requirements for listed companies.

The meeting was presided over by Director Vimal D. Shah (DIN: 01506655), who digitally signed the regulatory communication on February 14, 2026. The company has requested BSE Limited to take these developments on record as part of their ongoing compliance obligations.

Norris Medicines Limited has informed the stock exchanges about the resignation of Ms. Sathya Venkatachalam from her position as Independent Director, effective December 12, 2025. The company made this disclosure under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

Director Resignation Details

Ms. Sathya Venkatachalam (DIN: 06970735) submitted her resignation letter dated December 10, 2025, with the resignation becoming effective from December 12, 2025. The director cited personal reasons for her decision to step down from the board.

Committee Positions

Following her resignation from the board, Ms. Venkatachalam has also stepped down from all company committees where she held membership. Notably, she served as the Chairperson of the Audit Committee at Norris Medicines Limited.

Regulatory Compliance

The company has fulfilled its disclosure obligations by providing the required information under Regulation 30 read with Schedule III-Part A(7B) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The disclosure also complies with relevant SEBI circulars including CIR/CFD/CMD/4/2015 dated September 9, 2015, and SEBI/HO/CFD/CFD-PoD1/P/CIR/2023/123 dated July 13, 2023.

Director's Confirmation

Ms. Sathya Venkatachalam has confirmed that there are no other material reasons for her resignation beyond the personal reasons mentioned in her resignation letter. This confirmation was provided as part of the regulatory disclosure requirements for director resignations.

The resignation letter and related documentation have been submitted to BSE Limited, where Norris Medicines Limited is listed with scrip code 524414 and ISIN INE744C01029.